Results 131 to 140 of about 82,244 (295)

Expanding buprenorphine prescribing in primary care: a qualitative study of the experiences of primary care providers and nurse care managers participating in the New York City buprenorphine nurse care manager initiative

Harm Reduction Journal
Background Improving access to and retention in evidence-based treatment for opioid use disorder, including buprenorphine, is a critical response to the opioid overdose crisis.
Elodie C. Warren, Nisha Beharie, Marissa Kaplan-Dobbs, Asmara Tesfaye Rogoza, Alex Harocopos   +4 more
doaj   +1 more source

The Polysubstance Assessment Tool: Reliability, acceptability and feasibility of a novel measure of polysubstance use

Addiction, EarlyView.
Abstract Background and aims There are currently no brief quantitative assessments that capture the drug patterns of people who engage in use of more than one drug on the same day or simultaneously. The current study examined the retest reliability, acceptability and feasibility of a new quantitative assessment to measure polysubstance use.
Amanda M. Bunting, Charles M. Cleland, S. Michaela Barratt, Brittany Griffin, Jaimee Williams, Carrie B. Oser, Joshua D. Lee, Jennifer McNeely   +7 more
wiley   +1 more source

Psychosocial interventions and opioid detoxification for drug misuse: summary of NICE guidance [PDF]

, 2007
Drug misuse is an increasing problem that not only impairs the physical and mental health of people who misuse drugs but also negatively affects their families and wider society (for example, in its association with crime).
Gerada, Clare, Pilling, Stephen, Strang, John   +2 more
core  

Theorizing causality: A qualitative study of xylazine‐related wound diversity and perceived etiology among people who inject drugs

Addiction, EarlyView.
Abstract Background and aims Incidence and severity of opioid‐associated skin and soft‐tissue infections, often requiring intensive and costly medical care, have increased substantially since the emergence of xylazine in the US drug supply. Although progress has been made in clinical and harm reduction recommendations for treating xylazine‐related ...
Danielle German, Kelci Villarroel, Meredith Denney, Adrian Guta, Julie Evans, Jason Bienert, Alex Fidler, Kim Ashburn, Zach Kosinski, Becky L. Genberg   +9 more
wiley   +1 more source

全身麻酔下家兎を用いたブプレノルフィンによる中枢性呼吸抑制に対するドネペジルによる拮抗作用 [PDF]

, 2016
Buprenorphine is a mixed opioid receptor agonist-antagonist used in acute and chronic pain management. Although this agent\u27s analgesic effect increases in a dose-dependent manner, buprenorphine-induced respiratory depression shows a marked ceiling ...
櫻庭 茂樹
core   +1 more source

Healthcare utilization and mortality after overdose prevention site closure: A linked cohort analysis using segmented difference‐in‐differences time series

Addiction, EarlyView.
Abstract Background and aims Evidence regarding the impacts of supervised drug consumption services (SDC) remains mixed, and few evaluations have used individual‐level, linkable health data to examine service withdrawal. In September 2024, the Red Deer overdose prevention site (OPS) in Alberta, Canada, was scheduled for closure, with operations ceasing
Nathaniel Day, Kym Kaufmann, Daniel John Alexander Devoe, Vanja Grubac, Alessia DiMarzo, Haisa Osmanli, Vanessa Norton, Shelly Vik, Nickie Mathew, Robert Lawrence Tanguay, Anees Bahji   +10 more
wiley   +1 more source

Cross-sectional examination of characteristics of higher-dose buprenorphine prescriptions during the era of illicit fentanyl

Addiction Science & Clinical Practice
Background In response to greater illicit fentanyl use, buprenorphine daily doses exceeding the FDA’s recommended target daily dose (16 mg) and maximum suggested daily dose (24 mg) may provide better outcomes, but little is known about higher dosage ...
Bradley D. Stein, Flora Sheng, Brendan K. Saloner, Adam J. Gordon, Jessica S. Merlin   +4 more
doaj   +1 more source

The association between sleep disturbance and stimulant use: A cross‐lagged examination

Addiction, EarlyView.
Abstract Background and aims Sleep disruptions increase the risk of substance misuse. Substance use—especially stimulants—can increase acute and chronic sleep dysfunction. This study aimed to estimate the associations between sleep disturbance and stimulant use over time among participants with stimulant use disorder (StUD).
Viviana E. Horigian, Renae D. Schmidt, Daniel J. Feaster, Rui Duan, Sophia T. Gonzalez, Kathryn Hefner, Dikla Shmueli‐Blumberg, Ashley Vena, Landhing M. Moran, Chloe A. DiCamillo, Shirin Shafazand, Susan Tross, Judith Feinberg   +12 more
wiley   +1 more source

Buprenorphine in Neonatal Abstinence Syndrome. [PDF]

, 2018
Infants exposed in utero to opioids will demonstrate a withdrawal syndrome known as neonatal abstinence syndrome (NAS). Buprenorphine is a long-acting opioid with therapeutic use in medication-assisted treatment of opioid dependency in adults and ...
Kraft, Walter K.
core   +1 more source

Unlocking ‘stuckness’ and catalysing change: A qualitative study of clinician and service leader perspectives on psychedelic‐assisted therapy for substance use and mental health problems

Addiction, EarlyView.
Abstract Background and aims Australia recently down‐scheduled and authorised psychedelic‐assisted therapies, including psilocybin, for certain mental health conditions. Evidence is emerging for potential application in substance use disorder treatment. However, regulatory developments have outpaced implementation readiness.
Sarah J. Catchlove, Katrin Oliver, Michael Savic, Shalini Arunogiri   +3 more
wiley   +1 more source